Our products are available in 65 countriesClick here and learn more
Our activities incorporate all areas of the pharmaceutical value chainClick here and learn more
Innovation is one of the pillars of our strategy. We devote approximately EUR 50 million to research and development.Click here and learn more
The quality of life of millions depends on the availability of our medicines. Egis is one of the leading generic pharmaceutical companies in Central Easter Europe. We produce approximately 170 million boxes of drugs, 700 tonnes of active pharmaceutical ingredients, 5 billion tablets, capsules annually. Our products are available in 65 countries, and annually more than 30 million patients’ recovery depends on Egis Group’s continuous operation.
The Semmelweis University and Egis Pharmaceuticals PLC have agreed on an even closer cooperation than before. Our common goal is to further raise the standards of pharmaceutical R+D as well as pharmacist and doctor training by making use of the synergies in each other’s activities. As a result of the agreement, new health industrial innovations can be launched and the Semmelweis University can be extended with more practical educational and training elements that also meet the needs of the Hungarian pharmaceutical industry.
To support the CSR activities of local companies, the Hungarian Business Responsibility founded its special awards, called CSR Hungary. This year, Egis was awarded in the ‘Inner CSR Solutions’ category that comes with a two-year trademark right.
Microsoft and HR Fest — the largest HR professional festival in Hungary — established a new professional award category within HR Best awards called ‘Future Proof Organizations’.
Egis Pharmaceutical PLC’s Senior pharmaceutical sales rep participated very successfully at Medigames. Having won two gold medals, four silvers, and three bronze, pharmacist Dr. Judit Karagics contributed considerably to the 3rd place Hungary reached in the medal table. This excellent performance strengthens Egis’ reputation in the international target groups.
Hungarian-based Egis Pharmaceuticals PLC signed an exclusive distribution agreement with Mundipharma network for a pegfilgrastim biosimilar. Pursuant to the agreement, Egis gains the exclusive distribution rights related to the medicine used to reduce a common side effect of cancer treatment called neutropenia and the related life-threatening infections. Thus, Egis gets the opportunity to launch this pegfilgrastim biosimilar product in four Eastern European countries.
Egis ’products are available in 65 countries. Our portfolio consists of 629 products. Our main focus lies on treating diseases of the cardiovascular and central nervous systems.Learn more about our products